Home » Stocks » ATRA

Atara Biotherapeutics, Inc. (ATRA)

Stock Price: $18.61 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $18.72 +0.11 (0.59%) Jan 15, 7:53 PM
Market Cap 1.54B
Revenue (ttm) n/a
Net Income (ttm) -303.81M
Shares Out 81.18M
EPS (ttm) -4.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $18.61
Previous Close $18.61
Change ($) 0.00
Change (%) 0.00%
Day's Open 18.83
Day's Range 18.34 - 19.19
Day's Volume 930,574
52-Week Range 5.69 - 26.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform t...

Investors Business Daily - 1 week ago

A Relative Strength Rating upgrade for Atara Biotherapeutics shows improving technical performance. The post Atara Biotherapeutics Clears Technical Benchmark, Hitting 80-Plus RS Rating appeare...

Business Wire - 1 week ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop tra...

Business Wire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform t...

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop tran...

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop trans...

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...

Business Wire - 1 month ago

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, devel...

Seeking Alpha - 1 month ago

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-...

Other stocks mentioned: ALLO, BMY, CLLS, CRSP, GILD, NVS, PFE
Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...

Seeking Alpha - 2 months ago

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop tran...

Investors Business Daily - 4 months ago

Atara Biotherapeutics sees its Relative Strength Rating reach the elite 90-plus level.

24/7 Wall Street - 4 months ago

24/7 Wall St. reviews dozens of analyst research reports each day of the week, and most of the so-called Buy and Outperform ratings come with upside of 8% to 10% for Dow Jones industrials, S&P...

Seeking Alpha - 4 months ago

Week 38 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Other stocks mentioned: AAPL, AXP, FVRR, HD, JNJ, JPM, KO, MRK, NKE, PFE, WMT
Zacks Investment Research - 4 months ago

Atara (ATRA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

24/7 Wall Street - 4 months ago

When it comes to life-threatening illnesses, mesothelioma would rank close to the top of the list.

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

Seeking Alpha - 5 months ago

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

Zacks Investment Research - 5 months ago

Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc.

Zacks Investment Research - 5 months ago

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor of Atara Biotherapeutics

The Motley Fool - 6 months ago

These companies offer promising pipelines that could deliver in the long term.

Other stocks mentioned: APRE
Business Wire - 6 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transf...

Zacks Investment Research - 6 months ago

Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

24/7 Wall Street - 7 months ago

Atara Biotherapeutics Inc. (NASDAQ: ATRA) is finding itself caught between a rock and a hard place after Friday’s drug study news.

Kiplinger - 7 months ago

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: DVAX, FIXX, GTHX, IMGN, KDMN, VKTX
Zacks Investment Research - 8 months ago

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 8 months ago

Atara Biotherapeutics (ATRA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Atara Biotherapeutics Inc (ATRA) CEO Pascal Touchon on Q1 2020 Results - Earnings Call Transcript

InvestorPlace - 8 months ago

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: BHVN, CBAY, MRNS, PTCT, SLDB, TBIO
The Motley Fool - 8 months ago

Amarin and Atara Biotherapeutics could both be diamonds in the rough.

Other stocks mentioned: AMRN
Seeking Alpha - 9 months ago

Atara Biotherapeutics: Still Bullish On Long-Term Prospects

Seeking Alpha - 10 months ago

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel t...

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading, off-the-shelf, allogeneic T-cell immunotherapy company developing novel ...

The Motley Fool - 11 months ago

These two cancer stocks are trading at a pittance compared to their long-term value propositions.

Other stocks mentioned: CLVS
Zacks Investment Research - 1 year ago

Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.

Other stocks mentioned: BOOT, MTUM, NKTR, ODP, ONEO, PDP, SPHB
Zacks Investment Research - 1 year ago

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

Other stocks mentioned: ALKS, AUTL, INVA, RTRX
Seeking Alpha - 1 year ago

Turnaround In Progress: Key Takeaways From Atara Biotherapeutics' Q3 Earnings Call

Zacks Investment Research - 1 year ago

Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

Atara Biotherapeutics' (ATRA) CEO Pascal Touchon on Q3 2019 Results - Earnings Call Transcript

About ATRA

Atara Biotherapeutics, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies f... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2014
CEO
Pascal Touchon
Employees
429
Stock Exchange
NASDAQ
Ticker Symbol
ATRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for ATRA stock is "Buy." The 12-month stock price forecast is 32.89, which is an increase of 76.73% from the latest price.

Price Target
$32.89
(76.73% upside)
Analyst Consensus: Buy